BioSpace News Archive

Keros Therapeutics, Inc. today announced that four abstracts will be presented at the 63rd American Society of Hematology (“ASH”) Annual Meeting and Exposition, to be held in person and virtually from December 11 through 14, 2021.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal therapeutic being developed for the treatment of systemic amyloidosis, will be presented at the 2021 American Society of Hematology Annual Meeting.

Keros Therapeutics, Inc. today provided a business update and reported financial results for the quarter ended September 30, 2021.

Senti Bio, a leading gene circuit company, announced that new preclinical data from its gene circuit-engineered allogeneic CAR-NK cell therapy pipeline will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition being held December 11–14.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced that a Trials in Progress abstract related to the Company’s lead candidate, ADI-001, has been accepted for an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition being held December 11-14, 2021.

Global Blood Therapeutics, Inc. announced that six abstracts related to its sickle cell disease programs, including data from the growing body of real-world evidence on Oxbryta® tablets and new data on GBT’s pipeline, will be presented at the 63rd American Society of Hematology Annual Meeting & Exposition.

Agios Pharmaceuticals, Inc. announced that a broad set of clinical and translational data from its genetically defined disease programs in chronic hemolytic anemias, including pyruvate kinase deficiency, thalassemia and sickle cell disease, will be presented at the American Society of Hematology Annual Meeting & Exposition, to be held Dec. 11-14, 2021, virtually and in person in Atlanta.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, reported financial results for the third quarter and nine months ended September 30, 2021.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will present two posters on its innate cell engagers at the 63rd American Society of Hematology Annual Meeting and Exposition.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming poster presentation at the 2021 American Society of Hematology Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA.